News AB Science

Equities

AB

FR0010557264

Real-time Euronext Paris Other stock markets 03:00:41 2024-04-19 am EDT			5-day change	1st Jan Change
1.992 ^EUR	+0.10%		-8.83%	-43.97%

Apr. 04	AB Science's Reconsideration Request for ALS Treatment Granted Eligibility in Canada	MT
Apr. 03	AB Science: reconsideration possible for masitinib in ALS	CF

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

AB Science's Reconsideration Request for ALS Treatment Granted Eligibility in Canada	Apr. 04	MT
AB Science: reconsideration possible for masitinib in ALS	Apr. 03	CF
AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALS	Apr. 03	GL
AB Science Announces Eligibility granted by Health Canada for Reconsideration Request for Masitinib in ALS	Apr. 03	CI
AB Science: encouraging results for masitinib	Mar. 13	CF
AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease	Mar. 13	GL
AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease	Mar. 13	AQ
AB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science development	Mar. 07	GL
AB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science development	Mar. 07	AQ
AB Science announces that two financial analysis firms, DNA Finance and In Extenso Finance, have initiated coverage of the Company	Mar. 06	GL
Transcript : AB Science S.A. - Special Call	Mar. 04
AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET	Mar. 01	GL
AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET	Feb. 29	GL
AB Science: share price falls, negative opinion in Canada	Feb. 27	CF
AB Science announces that Health Canada has issued a Notice of Non-Compliance-Withdrawal (NON/w) for masitinib in ALS	Feb. 26	GL
AB Science: share price falls, CHMP verdict postponed	Jan. 29	CF
AB Science announces an update in the marketing authorization application of masitinib in amyotrophic lateral sclerosis at the European Medicines Agency	Jan. 26	GL
AB Science: medical use patent for masitinib	Jan. 15	CF
AB Science receives notice of allowance for European patent covering masitinib until 2036 in the treatment of mastocytosis	Jan. 15	GL
AB Science Receives Notice of Allowance for European Patent Covering masitinib Until 2036 in the Treatment of mastocytosis	Jan. 15	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News AB Science

Equities

AB

FR0010557264

Summary

Filters